Gilead Sciences, Inc. with ticker code (GILD) now have 28 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $123.00 and $69.00 calculating the mean target share price we have $87.22. (at the time of writing). Given that the stocks previous close was at $88.78 this is indicating there is a potential downside of -1.8%. The 50 day MA is $82.36 and the 200 day moving average is $74.12. The total market capitalization for the company now stands at 110.80B. Currently the stock stands at: $89.00 USD
The potential market cap would be $108,857,110,110 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 108.54, revenue per share of $22.30 and a 11.55% return on assets.
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.
